Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster display

3747 - Large scale DFNA5 methylation and expression analysis in primary breast adenocarcinoma using data from the Cancer Genome Atlas


10 Oct 2016


Poster display


Lieselot Croes


Annals of Oncology (2016) 27 (6): 15-42. 10.1093/annonc/mdw363


L. Croes1, M. Beyens1, E. Franssen2, A. Goepfert1, M. Peeters3, P. Pauwels4, G. Van Camp2, K. Op De Beeck1

Author affiliations

  • 1 Oncology - Medical Genetics, University of Antwerp-Campus Drie Eiken, 2610 - Antwerp/BE
  • 2 Medical Genetics, University of Antwerp-Campus Drie Eiken, 2610 - Antwerp/BE
  • 3 Department Of Oncology, University Hospital Antwerp, 2650 - Edegem/BE
  • 4 Department Of Molecular Pathology, University Hospital Antwerp, 2650 - Edegem/BE


Abstract 3747


Methylation of promotor CpG islands is frequently associated with transcriptional silencing and may serve as a mechanism to inactivate tumor suppressor genes in breast cancer. We hypothesize that DFNA5 promotor methylation may be a valuable epigenetic biomarker, based upon strong indications for its role as tumor suppressor gene, its function in programmed cell death and its potential role as biomarker in cancer.


In this study we analyzed DFNA5 methylation in a high number of samples using publicly available data from TCGA. Infinium HumanMethylation450k data, covering 22 different CpGs in the DFNA5 gene, from 668 female breast adenocarcinoma samples and 79 paired normal breast samples were obtained. Agilent 244K Custom Gene Expression data were obtained for 476 female breast adenocarcinoma samples and 55 paired normal breast samples.


A significant difference in DFNA5 methylation (N = 79) between primary tumor and paired normal breast samples was found for all 22 CpGs (p 


These preliminary data suggest a promising role of DFNA5 in breast cancer. In addition, this analysis shows the power of initiatives such as TCGA, providing data for large sample numbers, for the analysis of individual genes involved in cancer.

Clinical trial identification

Legal entity responsible for the study

University of Antwerp


FWO, University of Antwerp


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings